Nasdaq · Biotech stocks database
CMND — Clearmind Medicine Inc. ☆
CMND (Clearmind Medicine Inc.) stock: $5.55, $2.8M market cap, $3.9M cash, -$1.1M EV, $1.9M fully diluted market cap. Next expected readout: Dec-26. Lead program: CMND-100 (Alcohol Use Disorder), Phase 2. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Our principal executive offices are located at 101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $3.9M Debt $0.0M Net cash $3.9M Enterprise value -$1.1M Basic shares 0.1M shares Fully diluted shares 0.3M shares Fully diluted market cap $1.9M Cash per share $26.13 Quarterly burn $2.1M Cash runway 1.9 quarters
Cash figures as of 2025-10-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-10-31.
Price history Loading CMND daily closes…
Loading price history…
Next catalyst CMND-100 · Feb 11 - Mar 25 in 14 wks · Phase 1/2 · Alcohol Use DisorderAll upcoming catalysts →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Feb 11 - Mar 25 in 14 wks CMND-100 Phase 1/2 Alcohol Use Disorder —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
Pipeline Lead drug CMND-100 Lead indication Alcohol Use Disorder Lead phase Phase 2 Active trials 1
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT05913752 Phase 1/2 Recruiting Sponsor Clearmind Medicine Inc. — Alcohol Use Disorder —
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 1 active trials for Clearmind Medicine Inc. on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.